Background: Recent evidence suggests that 2-week treatment with the non-psychotomimetic cannabinoid cannabidivarin (CBDV) could be beneficial towards neurological and social deficits in early symptomatic Mecp2 mutant mice, a model of Rett syndrome (RTT). Aim: The aim of this study was to provide further insights into the efficacy of CBDV in Mecp2-null mice using a lifelong treatment schedule (from 4 to 9 weeks of age) to evaluate its effect on recognition memory and neurological defects in both early and advanced stages of the phenotype progression. Methods: CBDV 0.2, 2, 20 and 200 mg/kg/day was administered to Mecp2-null mice from 4 to 9 weeks of age. Cognitive and neurological defects were monitored during the whole treatment schedule. Biochemical analyses were carried out in brain lysates from 9-week-old wild-type and knockout mice to evaluate brain-derived neurotrophic factor (BDNF) and insulin-like growth factor-1 (IGF-1) levels as well as components of the endocannabinoid system. Results: CBDV rescues recognition memory deficits in Mecp2 mutant mice and delays the appearance of neurological defects. At the biochemical level, it normalizes BDNF/IGF1 levels and the defective PI3K/AKT/mTOR pathway in Mecp2 mutant mice at an advanced stage of the disease. Mecp2 deletion upregulates CB1 and CB2 receptor levels in the brain and these changes are restored after CBDV treatment. Conclusions: CBDV administration exerts an enduring rescue of memory deficits in Mecp2 mutant mice, an effect that is associated with the normalization of BDNF, IGF-1 and rpS6 phosphorylation levels as well as CB1 and CB2 receptor expression. CBDV delays neurological defects but this effect is only transient.
Introduction
Rett syndrome (RTT) is an X-linked dominant neurodevelopmental disorder with a prevalence rate of 1 in 10,000 females. RTT patients have apparently normal perinatal development until about 6-18 months of age, after which they undergo a period of rapid regression, characterized by the appearance of autistic features, cognitive regression, stereotypic hand movements and loss of language. RTT girls also have seizures during childhood, breathing arrhythmias, develop scoliosis and lose mobility between ages 1 and 4 years (Chahrour and Zoghbi, 2007; Hagberg, 2002; Neul et al., 2014) .
Mutations affecting the methyl-CpG-binding protein 2 (MeCP2) represent the almost exclusive cause of the disorder (Amir et al., 1999) . Given the location of the MECP2 gene on the X chromosome, males with MECP2 mutations are more severely affected and rarely survive infancy while females, owing to X chromosome inactivation, are mosaics with cells that express either the wild-type (WT) or mutant version of MeCP2 (Chahrour and Zoghbi, 2007) .
Mecp2 deficiency in mice closely mimics the clinical features of the human disorder, including motor and neurological defects and breathing abnormalities (Ricceri et al., 2008) , possibly reflecting the high conservation of the MeCP2 amino acid sequence and the parallel dynamics of MeCP2 expression during brain development in the two species. Thus, despite differences in brain structure and developmental timing between humans and mice, the molecular consequences of the MeCP2 mutation appear to be similar in the two species, and mouse models represent an essential tool for testing potential treatment strategies for RTT.
Converging evidence points to a role for endocannabinoid signalling dysregulation in the pathophysiology of neurodevelopmental conditions including social dysfunction and autism spectrum disorder (ASD) (Karhson et al., 2016; Wei et al., 2017; Zamberletti et al., 2017) . Remarkably, improvement in social functioning and anxiety-like behaviour was consistently reported following pharmacological modulation of different components of the endocannabinoid system in genetic and environmental models of autism (Busquets-Garcia et al., 2013; Gomis-González et al., 2016; Hosie et al., 2018; Jung et al., 2012; Kerr et al., 2016; Servadio et al., 2016; Wei et al., 2016) . In line with animal data, recent human findings support a link between altered endocannabinoid activity and autism (Karhson et al., 2018) , possibly suggesting that compounds acting on the endocannabinoid system could be beneficial in alleviating ASD symptoms.
Phytocannabinoids are terpenophenolic constituents of the Cannabis sativa plant that, in addition to their effects on the endocannabinoid system, exhibit a range of neuromodulatory, neuroprotective, anti-oxidant and anti-inflammatory properties, including effects on biochemical pathways that could contribute to achieve an overall therapeutic effect in major neurological disorders (Campos et al., 2016; Fernandez-Ruiz et al., 2013; Hill et al., 2012b; Ligresti et al., 2016; Nagarkatti et al., 2009 ). Delta-9-tetrahydrocannabinol (THC) is the major psychotomimetic component of cannabis whose euphoric effects are mediated by the activation of CB1 receptors in the central nervous system; however, this mechanism is responsible for many untoward adverse effects, whose risk is greater with early use and high doses (Volkow et al., 2014) , thus discouraging its use among children and high-risk groups. Unlike THC, other phytocannabinoids with weak or no psychotropic activity seem to hold great yet unexplored promise as therapeutic agents for complex and multifaceted neurodevelopmental diseases. Cannabidiol (CBD) and cannabidivarin (CBDV) are both effective in ameliorating epilepsy (Brodie and Ben-Menachem, 2018 ) and motor dysfunctions (Iannotti et al., 2018) , two conditions frequently observed also in RTT patients (Huppke et al., 2007; Steffenburg et al., 2001) , supporting their potential as treatment options for RTT. Accordingly, a recent paper showed that a 2-week-long treatment schedule with CBDV could be beneficial towards neurological and social deficits in early symptomatic Mecp2 mutant mice, a model for RTT, possibly via its action at GPR55 receptors (Vigli et al., 2018) . Both CBD and CBDV activate and desensitize TRPV1 cation channels and modulate anandamide uptake. Additionally, CBDV also modulates the levels of the endocannabinoid 2-AG (De Petrocellis et al., 2011 , which is crucially involved in synaptic plasticity and cognitive processes (Zhang et al., 2014) .
To gain more insight into the possible efficacy of CBDV in the context of RTT, in this study we provided additional pieces of data by testing the effect of similar doses of CBDV in another animal model of RTT, namely Mecp2-null mice, using a lifelong treatment schedule (from 4 to 9 weeks of age). CBDV effects on recognition memory and neurological deficits were monitored throughout the entire animals' lifespan. At an advanced stage of the phenotype progression (9-week-old mice), biochemical analysis was performed to assess whether CBDV could modulate neurochemical abnormalities that are found in the brain of Mecp2-null mice. In particular, we investigated CBDV's effect on brain-derived neurotrophic factor (BDNF), insulin-like growth factor-1 (IGF-1) and their common downstream PI3K/ Akt/mTOR signalling pathway, whose reduced levels have been implicated in the disease progression (Castro et al., 2014; Li and Pozzo-Miller, 2014; Ricciardi et al., 2011) , and we analyzed nuclear volumes in the layer V of the medial prefrontal cortex (mPFC) and CA1 region of the hippocampus, whose reduction represents a consistent feature of Mecp2 deficiency at the cellular level (Gadalla et al., 2013; Giacometti et al., 2007) . Finally, given that altered endocannabinoid activity contributes to the pathogenesis of several psychiatric conditions including anxietyrelated disorders, intellectual disabilities, major motor disorders, seizures and autism (Campolongo and Trezza, 2012; Fernández-Ruiz and Gonzáles, 2005; Katona, 2015; Zamberletti et al., 2017) , we investigated the status of components of the endocannabinoid system, in terms of endocannabinoid levels, enzymatic machinery and CB1, CB2 receptors.
Experimental procedures
Animals. We used the CD1 Mecp2-null mouse strain described in Cobolli Gigli et al. (2016) . All experimental procedures were carried out in male Mecp2 WT and KO mice, housed in groups of four to five in clear plastic cages (33.1×15.9×13.2 cm) on a 12-h light-dark cycle (lights on 8:00 a.m.) and in a temperature-(22 ± 2°C) and humidity-controlled environment (50 ± 10%) with a plastic tube for environmental enrichment and free access to food and water. Experimental procedures were performed in accordance with the guidelines released by the Italian Ministry of Health (D.L. 2014/26) and the European Community directives regulating animal research (2010/63/EU). Protocols were approved by the Italian Minister for Scientific Research, and all efforts were made to minimize the number of animals used and their suffering.
Breeding procedure and genotyping. Wild-type CD1 males and Mecp2 +/-heterozygous CD1 females aged between 2 and 4 months were mated for 4 days. Dams gave birth and raised their litters until weaning. Litters were not culled and no selection other than genotype was made. Mouse genotypes were determined through PCR on genomic DNA purified from tail biopsy. Biopsies were obtained within the third and fourth week of life. Forward PCR primer sequences were: 5'-CCATGCGATAGGCTTGATGA for the identification of the null allele, 5'-GACCCCTTGGGACT-GAAGTT for the wt allele. The common reverse primer sequence was: 5'-CCACCCTCCAGTTTGGTTTA. The obtained PCR products were: a single band of 450 base pairs (bp) for the Mecp2-null mice; a single band of 400 bp for the wt animals and the two bands for heterozygous females.
Treatment
A total of 112 littermate male mice from four different cohorts were used in the study. Based on the available litters at weaning, animals were randomly divided into 10 treatment groups: 22 for WT-vehicle, 10 for WT-CBDV 0.2 mg/kg, 13 for WT-CBDV 2 mg/kg, 12 for WT-CBDV 20 mg/kg, 3 for WT-CBDV 200 mg/kg, 11 for KO-vehicle, 6 for KO-CBDV 0.2 mg/kg, 13 for KO-CBDV 2 mg/kg, 14 for KO-CBDV 20 mg/kg and 8 for KO-CBDV 200 mg/kg.
Purified CBDV (96.4%; CBD 3.6%) was provided by GW Research (Cambridge, UK), stored at −20°C and freshly prepared daily by dissolution in ethanol, kolliphor EL and saline (2:1:17). The treatments started at postnatal day (PND) 28 (week 4) and lasted until PND 67 (week 9). Mice received a daily intraperitoneal injection of CBDV (or vehicle) at the doses of 0.2, 2, 20 or 200 mg/kg between 9:00 a.m. and 11:00 a.m. based on previous pharmacokinetic (Deiana et al., 2012) and in vivo (Vigli et al., 2018) studies.
Behavioural studies
Behavioural testing was carried out by two observers blind to the treatment conditions. The timeline of the experiments is reported in supplementary Figure S1 .
Score test. Neurological defects in Mecp2-null mice were evaluated using observational scoring for hindlimb clasping, gait, breathing, tremor, mobility and general condition. Starting from PND 28, Mecp2 WT and KO mice were scored every other day to evaluate the effect of CBDV treatment on motor symptoms, neurological signs and general condition. Score data were expressed as the weekly average of 4-day observations in each corresponding week. Each of the six symptoms was scored from 0 to 2 (0 corresponds to the symptom being absent or the same as in the WT animal; 1 when the symptom was present; 2 when the symptom was severe) as previously described (Guy et al., 2007; Szczesna et al., 2014 ; see Supplementary Methods for a detailed description). Whenever a mouse scored 2 out of 2 in the three criteria tremor, breathing and general condition, or lost 20% of its body weight during the experiment, it was euthanized. Zamberletti et al. (2015) . Each animal was placed in the arena and allowed to explore two identical previously unseen objects for 10 min (familiarization phase). The test phase was performed after an inter-trial interval of 30 min. During the test phase, the time spent exploring the familiar object (Ef) and the new object (En) was recorded separately by two observers blind to the groups and the discrimination index was calculated as follows: (En − Ef)/(En + Ef) × 100. Objects were changed in subsequent testing sessions of the NOR test.
Novel object recognition (NOR) test.

Biochemical studies
Western blot. Mice having all the same age (9 weeks old) were sacrificed by cervical dislocation 24 h after the last CBDV (or vehicle) injection. The brains were quickly removed, frozen in liquid nitrogen and stored at −80°C.
Fifty micrograms of total protein lysates from hemisected brains were run on an SDS-polyacrylamide gel. The proteins were transferred to polyvinylidene difluoride (PVDF) membranes and blocked for 2 h before incubation overnight at 4°C with specific primary antibodies (listed in supplementary Table S1 ). Bound antibodies were detected with horseradish peroxidase (HRP) conjugated secondary anti-rabbit or anti-goat antibody (1:2000-1:5000; Chemicon International, Temecula, CA). The blots were normalized against mouse anti-β-actin monoclonal antibody (1:10,000; Sigma Aldrich, Italy), rabbit polyclonal anti-totalAKT (1:1000; Abcam, Cambridge, UK), rabbit polyclonal anti-totalS6 (1:1000; Cell Signaling, Danvers, MA) or rabbit polyclonal antitotalERK1/2 (1:1000; Cell Signaling, Danvers, MA, USA). Bound antibodies were visualized using Clarity Western ECL Substrate (Bio-Rad Laboratories, Hercules, CA, USA), and bands were detected with a GBOX XT camera (Syngene, Cambridge, UK). Optical density of the bands was quantified using Image Pro Plus 7.0 software (MediaCybernetics, Bethesda, MD, USA), normalized and expressed as arbitrary units.
Lipid extraction and endocannabinoid measurement. Hemisected brains were dounce-homogenized and extracted with acetone containing internal deuterated standards for anandamide (AEA), palmitoylethanolamide (PEA), oleoylethanolamide (OEA) and 2-arachidonoylglycerol (2-AG) quantification by isotope dilution LC-MS, i.e. 5 pmol d8-AEA, and 50 pmol d4-PEA, d4-OEA and d5-2-AG (Cayman Chemical), respectively. The lipid-containing organic phases were then purified by open bed chromatography on silica, and fractions were obtained by eluting the column with 99:1, 90:10 and 50:50 (v/v) chloroform/methanol. Fractions eluted with chloroform/methanol 90:10 were collected, the excess solvent evaporated with a rotating evaporator, and aliquots analyzed by isotope dilution LC/atmospheric pressure chemical ionization/MS carried out in the selected ion monitoring mode by using a Shimadzu HPLC apparatus (LC-10ADVP) coupled to a Shimadzu (LCMS-2020) quadrupole mass spectrometer via a Shimadzu atmospheric pressure chemical ionization interface. MS detection was performed by using values of m/z 356 and 348 (molecular ions + 1 for d8-AEA and AEA), m/z 304 and 300 (molecular ions + 1 for d4-PEA and PEA), m/z 330 and 326 (molecular ions + 1 for d4-OEA and OEA) and m/z 384 and 379 (molecular ions +1 for d5-2-AG and 2-AG). AEA, PEA, OEA and 2-AG levels were therefore calculated on the basis of their area ratios with the internal deuterated standard signal areas. Lipid amounts expressed as pmol were then normalized per gram or milligram of wet tissue.
Immunohistochemistry. Frozen brain sections were obtained using a Leica cryostat CM1510 set to 20-μm thickness and a −20°C chamber temperature. Sagittal sections were collected on gelatin-coated slides (four sections per slide, 200 μm apart) and permeabilized with 100% methanol at −20°C for 30 min. After three washes in 0.05% Triton X-100 in TBS, sections were blocked with 3% normal goat serum in TBS for 1 h at room temperature and then incubated overnight at 4°C with rabbit antiphospho-rpS6 (Ser240/244) (1:50) from Cell Signaling Technology (Danvers, MA, USA) diluted in blocking solution. After blocking peroxidase activity with 0.3% H 2 O 2 in TBS for 15 min, sections were washed in TBS and incubated for 4 h at room temperature with goat anti-rabbit horseradish peroxidase (HRP) conjugated secondary antibody diluted 1:100 (Vector Labs, Burlingame, CA, USA). The sections were then incubated in chromogen 3,3'-diaminobenzidine tetrahydrochloride (DAB) for 5 min. The reaction was stopped in PBS and sections were dehydrated and cover slipped.
Digital Images were captured using Retiga R1 CCD camera (QImaging, Surrey, BC, Canada) attached to an Olympus BX51 (Tokyo, Japan) polarizing/light microscope. Ocular imaging software (QImaging) was used to import images from the camera. Images of layer V neurons in the medial prefrontal cortex were acquired by first delineating the brain sections and the regions of interest (ROI) at low magnification (×4 objective), and the ROI were further refined under a ×40 objective. Labelled cells were counted manually in every ten 20-μm-thick sagittal section (200 μm apart) within the ROI using a 300 × 300 μm grid as reference. Three mice per each experimental group (four sections/ mouse) were analyzed blinded.
Nuclear size measurements. For DAPI staining, slides were pre-incubated in 80% methanol at 4°C for 5 min, washed in TBS for 10 min and then incubated in a working solution 1 to 10 in PBS from a 0.01% stock solution in the dark for 30 min at room temperature. After several washes in PBS, sections were dehydrated and cover slipped. Images of layer V neurons in the medial prefrontal cortex and of CA1 pyramidal cell layer were acquired using a ×20 objective after having defined the outlines of the ROI at low magnification (×4 objective). Outlines of nuclei were manually traced at ×20 image magnification using ImageJ software (NIH, Bethesda, MD, USA). Four slices of tissue from three animals per each experimental group (30-75 cells/animal) were analyzed blind to the treatment groups. Only in-focus neurons that were completely within the field of view and whose signal was not occluded by overlying cells were measured.
Statistics
The Shapiro-Wilk test was first used to determine if the data were normally distributed. Qualitative non-normally distributed score data were analyzed non-parametrically using Pearson's chisquare test with Yates correction. NOR data and biochemical results were expressed as mean ± SEM and analyzed by twoway repeated measures and main effects ANOVA, respectively, by the GLM package of Statistica 7.0. Tukey's post hoc test was used to control for multiple comparisons. Kaplan-Meier survival curves were generated and compared using a Dunnet-type logrank method. The level of statistical significance was set at p<0.05. Calculations were carried out using Statistica 7.0 and R (R Core Team, 2013) Statistical Software.
Results
Behavioural data
Effect of chronic CBDV treatment on motor and neurological sign progression in Mecp2-deficient male mice. Figure 1(a) shows the effect of chronic CBDV treatment on tremors, hind limb clasping, breathing, gait, mobility and general condition in KO mice over time. No symptoms were present in Mecp2 KO mice until 4 weeks of age (data not shown). Either WT mice treated with vehicle or CBDV did not show any symptom (score = 0) during the entire period of observation (data not shown). Impaired mobility and deterioration of general condition in KO mice was observed starting from 7 weeks of age. CBDV administration at all doses tested did not affect both parameters in KO mice during the whole treatment schedule.
To gain an overall impression of CBDV treatment in Mecp2 KO mice over time, individual behaviour scores were combined into a total symptom score for each mouse (Figure 1(b) ). Total symptom score was significantly increased in KO mice treated with vehicle starting from 5 weeks of age compared with WT mice and continued to increase until the end of the observation period. Significant effects were observed on total symptom score at 6 (χ 2
[8] =19.617, p=0.0037) and 7 (χ 2 [8] =21.732, p=0.0041) weeks of age. Treatment with CBDV 2, 20 and 200 mg/kg showed similar efficacy in attenuating motor and neurological deficits in KO mice. Indeed, they significantly improved total symptom score in KO mice at 6 (p<0.001) and 7 (p<0.001) weeks of age, although CBDV's beneficial effect was lost at later stages of the disease progression (i.e. 8 and 9 weeks of age). In contrast, CBDV 0.2 mg/kg did not affect the progression of symptoms over the entire observation period.
Effect of chronic CBDV treatment on survival and body weight in Mecp2-deficient male mice. Survival data refer to all mice that underwent behavioural assessment. Figure 2(a) shows the percentage survival of Mecp2 KO and WT mice treated with CBDV or vehicle. The results are plotted as KaplanMeier survival curves and expressed as the percentage of surviving mice over total mice with respect to time for each experimental group. No lethality was observed in WT mice treated with either vehicle or CBDV. In contrast, survival in KO mice treated with vehicle was only 38.5% by 9 weeks of age. All doses of CBDV showed a trend to increase survival rates in Mecp2 KO mice at the end of the observation period compared with vehicle-treated littermates (KO-CBDV 0.2 mg/kg: 66.6%; KO-CBDV 2 mg/kg: 61.5%; KO-CBDV 20 mg/kg: 71.4%; KO-CBDV 200 mg/kg: 87.5%), although this effect reached statistical significance only at the highest dose tested, 200 mg/kg (p=0.0433; log-rank test). Regarding body weight, as expected, Mecp2 KO mice were significantly leaner than WT littermates (Figure 2(b) ). Chronic CBDV administration did not recover body weight in KO mice, although a post hoc test did not reveal significant differences between WT-vehicle and KO mice treated with CBDV 2/20/200 mg/kg. Effect of chronic CBDV treatment on recognition memory deficits in Mecp2-deficient male mice. Figure 3 shows the effect of chronic CBDV administration on short-term recognition memory at PND 41, 56 and 66. No differences in exploratory behaviour and locomotor activity were observed in WT and KO mice during the training session of the recognition memory test (Supplementary Figure S2) . Exploration times of the novel object and the familiar object in the test phase are reported in Supplementary Figure S3 . Figure 4 (a)).
Two-way ANOVA analysis revealed significant effects of genotype (F [1, 38] =4.773, p=0.0032) and genotype × treatment interaction (F [4, 38] =2.709, p=0.0444) on IGF-1 levels. IGF-1 levels were significantly reduced in Mecp2 KO mice treated with vehicle compared with WT animals (p<0.05). CBDV significantly increased IGF-1 levels in KO mice at doses of 2 (p<0.05), 20 (p<0.05) and 200 (p<0.01) mg/kg (Figure 4(a) ).
A significant genotype × treatment interaction (F [4, 26] =6.574, p=0.0009) and a trend for genotype effect (F [1, 26] =3.967, p=0.0570) were found on pAKT levels (Figure 4(b) ). pAKT was significantly reduced in Mecp2 KO mice treated with vehicle compared with WT-vehicle animals (p<0.05). Chronic CBDV administration dose dependently recovered pAKT levels in Mecp2 deficient mice, reaching statistical significance at doses of 20 (p<0.01) and 200 (p<0.001) mg/kg.
Significant effects of genotype (F [1, 29] =23.83, p<0.0001) and genotype × treatment interaction (F [4, 29] =2.702, p=0.0500) on rpS6 phosphorylation were also observed. Mecp2 deletion significantly reduced rpS6 phosphorylation within the adult brain (p<0.001). Chronic CBDV treatment significantly increased rpS6 phosphorylation levels in KO mice compared with vehicletreated mutants at doses of 2 (p<0.05), 20 (p<0.01) and 200 (p<0.05) mg/kg.
Immunohistochemical analysis revealed significant effects of genotype (F [1, 20] =12.07; p=0.0024), treatment (F [4, 20] =3.042; p=0.0413) and genotype × treatment interaction (F [4, 20] =7.156; p=0.0010) on rpS6 phosphorylation in layer V neurons of the medial prefrontal cortex (Figure 4(c) ). Indeed, rpS6 phosphorylation was significantly decreased in Mecp2 KO mice compared with WT animals (p<0.05); CBDV administration significantly enhanced rpS6 phosphorylation in mutant mice at doses of 20 (p<0.05) and 200 (p<0.01) mg/kg without affecting its levels in WT animals. A trend towards an enhancement of rpS6 phosphorylation was also present in KO mice after administration of the 2 mg/kg dose (p=0.0717), whereas the 0.2 mg/kg dose was completely ineffective. Finally, neither genotype nor CBDV treatment affected ERK1/2 phosphorylation (Figure 4(b) ).
CBDV effect on nuclear areas in layer V neurons of the medial prefrontal cortex and in the CA1 layer of the hippocampus.
In the mPFC, the mean nuclear area of KO neurons was 35.5% smaller than that of WT neurons (WT-vehicle = 69.98 ± 2.091 μm 2 , KO-vehicle = 45.10 ± 1.208 μm 2 ; p<0.001, Figure 5(a) ). CBDV treatment, at all doses tested, did not affect nuclear size in KO neurons (CBDV 0.2 mg/kg = 40.48 ± 1.598 μm 2 , CBDV 2 mg/kg = 47.71 ± 1.779 μm 2 , CBDV 20 mg/kg = 48.44 ± 1.782 μm 2 , CBDV 200 mg/kg = 53.08 ± 2 μm 2 ). In the CA1 layer of the hippocampus, the mean nuclear area of KO neurons was 32.3% smaller than that of WT neurons (WT-vehicle = 63.5 ± 2.237 μm 2 , KO-vehicle = 43.0 ± 1 μm 2 ; p<0.001, Figure 5(b) ). A partial rescue of hippocampal neuron nuclear size was observed in KO mice after chronic CBDV administration at doses of 2, 20 and 200 mg/kg (CBDV 2 mg/kg = 53.46 ± 1.721 μm 2 , CBDV 20 mg/ kg = 52.55 ± 1.982 μm 2 , CBDV 200 mg/kg = 51.66 ± 1.650 μm 2 ) but not 0.2 mg/kg (CBDV 0.2 mg/kg = 47.26 ± 1.862 μm 2 ).
Effect of chronic CBDV treatment on cannabinoid CB1 and CB2 receptors in Mecp2-deficient male mice. Two-way
ANOVA analysis revealed significant effects of genotype and genotype × treatment interaction on CB1 (F [1, 32] =19. 89, p<0.0001; F [4,32] =3.429, p=0.0193) and CB2 (F [1, 32] =4.662, p=0.0384; F [4,32] =3.834, p=0.0118) receptors (Figure 6 ). CB1 levels were significantly increased in Mecp2 KO mice treated with vehicle compared with WT-vehicle littermates (p<0.001). Chronic CBDV treatment significantly reduced CB1 receptor expression in KO mice at doses of 2 (p<0.05), 20 (p<0.05) and 200 (p<0.05) mg/kg. CBDV at all doses tested did not affect CB1 receptor levels when chronically administered to WT animals. CB2 receptor expression was significantly enhanced in Mecp2 KO mice treated with vehicle compared with WT-vehicle controls (p<0.001). Chronic CBDV administration significantly rescued CB2 receptor expression in KO mice at doses of 2 (p<0.001), 20 (p<0.001) and 200 (p<0.001) mg/kg, without affecting its levels in WT littermates.
Effect of chronic CBDV treatment on endocannabinoid contents in Mecp2-deficient male mice.
No statistically significant differences in AEA, OEA, PEA and 2-AG levels were found between the two genotypes, although a trend for the increase of AEA (p=0.0613) and OEA (p=0.0817) was noticed in KO mice (Figure 7(a) ). Statistical analysis revealed significant effects of genotype × CBDV treatment interaction on AEA (F [4, 20] =5.859, p=0.045) and 2-AG (F [4, 20] =5.375, p=0.041) levels as well as a non-significant trend on OEA (F [4, 20] =8.787, p=0.067) content. CBDV administration at doses of 2 (p<0.05), 20 (p<0.001) and 200 (p<0.01) mg/kg significantly increased AEA levels in Mecp2 KO mice with respect to WT-vehicle mice. A similar effect of CBDV was also observed on OEA levels. Indeed, CBDV at 2 (p<0.01), 20 (p<0.001) and 200 (p<0.05) mg/kg significantly enhanced OEA content. Chronic CBDV administration significantly reduced 2-AG levels in the brain of KO mice at doses of 20 (p<0.05) and 200 (p<0.01) mg/kg compared with vehicle-treated animals. CBDV treatment also showed a trend towards reduction of 2-AG levels in WT mice. Finally, CBDV treatment did not affect PEA content in the brain of both WT and KO animals. (Figure 7(b) ). The expression of the main AEA synthetic enzyme NAPE-PLD was significantly increased in male Mecp2 KO mice after chronic treatment with CBDV at the highest dose tested (p<0.01). In contrast, CBDV treatment at the lowest doses did not affect NAPE-PLD levels both in Mecp2 WT and KO mice. Deletion of Mecp2 resulted in a significant reduction of FAAH levels (p<0.05) that were not rescued by chronic CBDV administration. In addition, chronic treatment with CBDV showed a trend towards a reduction in FAAH expression in WT mice at doses of 0.2 and 20 mg/kg. CBDV treatment also affected the expression of DAGLα, a key enzyme in the biosynthesis of the endocannabinoid 2-AG. In fact, chronic CBDV administration significantly reduced DAGLα protein levels at all doses tested both in WT (p<0.01) and in KO (p<0.001) mice. No effect of either genotype or CBDV treatment was observed on the 2-AG degrading enzyme MAG lipase.
Effect of chronic CBDV treatment on endocannabinoid synthetic and degrading enzymes in
Protein levels of BDNF, p-rpS6, endocannabinoid receptors and enzymes in the brain of pre-symptomatic 4-week-old mice.
In order to establish whether the expression of BDNF and p-rpS6 as well as endocannabinoid receptors and synthetic/ degrading enzymes was altered in an apparently asymptomatic phase of the phenotype progression, we performed Western blot analysis in brain lysates from 4-week-old WT and KO mice, i.e. before starting CBDV treatment. As reported in Supplementary Figure S4 , both BDNF and rpS6 phosphorylation levels were significantly reduced in 4-week-old Mecp2-null mice compared with WT animals by about 48.3% and 35.9%, respectively. In contrast, no alteration in the expression of CB1 and CB2 receptors was present at this stage of the phenotype progression. Similarly, no changes were found in the main endocannabinoid synthetic and degrading enzymes, although a trend towards a reduction in MAG lipase expression was present (p=0.0805). 
Discussion
Chronic administration of the non-psychotomimetic phytocannabinoid CBDV completely recovers recognition memory deficits in Mecp2 KO animals and this improvement persists at advanced stages of the phenotype progression. Furthermore, CBDV prolongs survival and delays the appearance of neurological and motor signs in Mecp2 KO mice in a time window between 6 and 7 weeks of age. This last effect is in line with previous findings by Vigli et al. (2018) showing that 14 days of treatment with similar doses of CBDV improves the general health status, the social sphere and the motor skills in MeCP2-308 male mice. However, our study provides additional information supporting that CBDV's beneficial effect on motor and neurological signs is only transient and is lost when a longer treatment schedule (5 weeks long) is applied. Thus, the effect of CBDV might be explained better as a delay in the onset of the neurological defects rather than a reduction in their intensity at a specific age.
From a pharmacological point of view, CBDV does not show a linear dose-response curve, but it elicits an "all-or-none" response, as doses of 2, 20 and 200 mg/kg show similar efficacy in ameliorating the phenotype of Mecp2 mutant mice, whereas the lowest dose tested, 0.2 mg/kg, is completely ineffective. Although a steep dose-response effect might exist between 0.2 and 2 mg/kg, CBDV's non-linear dose-response curve could be a consequence of drug tolerance following repeated exposure or target desensitization. However, a final explanation must await the identification of the specific target responsible for CBDV's effects in this model. In addition, we cannot rule out the possibility that CBD content in our preparation, which is primarily CBDV (96.4%), but also contains low levels of CBD (3.6%), might have affected CBDV pharmacokinetics. In fact, different dose-response curves can be observed when cannabinoids are administered in isolation or in combinations that contain also low levels of other phytocannabinoids (Gallily et al., 2015; Zuardi et al., 2017) .
Also, we cannot exclude that CBD could participate in the overall effects of drug treatment reported in this study, as significant neuroprotective effects of this phytocannabinoid were reported in conditions including depression, anxiety, stroke and neurodegenerative diseases even at very low doses (Campos et al., 2017; Crippa et al., 2018) and low doses of CBD improved cognition, motor activity and BDNF levels in animal models (Avraham et al., 2011; Magen et al., 2010) .
Biochemical studies performed at an advanced stage of the phenotype shows that CBDV treatment simultaneously elevates the levels of BDNF and IGF-1 in the brain of clearly symptomatic Mecp2 KO mice at behaviourally efficacious doses.
Expression of BDNF is decreased in mouse models of RTT (Chang et al., 2006; Chen et al., 2003; Li and Pozzo-Miller, Representative blot images correspond to the results of one experiment out of four. Data are expressed as mean ± SEM of three to six animals per group and were analyzed by two-way ANOVA followed by Tukey's multiple comparison test. *p<0.05, **p<0.01, ***p<0.001 vs WTvehicle; °p<0.05, °°p<0.01, 2014; Martinowich et al., 2003) , and enhancement of BDNF levels in vivo relieves some symptoms of the mutant phenotype (Chang et al., 2006; Deogracias et al., 2012; Johnson et al., 2012; Kline et al., 2010; Kron et al., 2014; Ogier et al., 2007; Roux et al., 2012; Schmid et al., 2012) . Unfortunately, the therapeutic potential of BDNF is limited by its poor efficiency at crossing the blood-brain barrier (Pardridge et al., 1994) . Hence, possible therapeutic strategies must rely on the identification of agents capable of indirectly stimulating BDNF levels. Remarkably, our data support CBDV potential to modulate BDNF levels in Mecp2-null mice.
CBDV treatment also increases IGF-1 levels in the brain of mutant mice. IGF-1 is another neurotrophic factor that holds great promise as a therapeutic agent in RTT. Like BDNF, IGF-1 is widely expressed in the brain during development (Dyer et al., 2016) . In mouse models, administration of both IGF-1 and its truncated form (1-3)IGF-1 reverses many of the features of the RTT phenotype (Castro et al., 2014; Chen and Russo-Neustadt, 2007; Della Sala et al., 2016; Tropea et al., 2009) , and early studies in RTT patients have demonstrated the tolerability and safety of IGF-1 as a potential treatment (Khwaja et al., 2014; Pini et al., 2012 Pini et al., , 2014 Pini et al., , 2016 .
Although both BDNF and IGF-1 signal via PI3K/AKT and MAPK/ERK pathways to affect neuronal maturation and survival (Tropea et al., 2006; Yoshii and Constantine-Paton, 2007; Zheng and Quirion, 2004) , there is direct evidence of the involvement of the AKT pathway in RTT. Reduced phosphorylation of rpS6 in Mecp2-deficient mice is specific to signalling via AKT and not ERK1/2 kinases (Ricciardi et al., 2011) . Worth noting, CBDVmediated increases of BDNF and IGF-1 are associated with the normalization of their common downstream AKT/mTOR signalling pathway, whereas no effects of either genotype or CBDV treatment are observed on ERK1/2 expression. Interestingly, reduced phosphorylation of rpS6 in Mecp2-deficient mice is most intense in the mPFC, in line with recent studies supporting a contribution of mPFC hypofunction to the development of RTT-like phenotypes (Howell et al., 2018; Sceniak et al., 2016) . In particular, excitatory hypoconnectivity in the mPFC has been linked to cognitive impairments in Mecp2 mutant mice (Howell et al., 2018) possibly suggesting that CBDV's ability to normalize rpS6 phosphorylation in the mPFC could contribute to its beneficial effect on memory impairments. Consistent with this hypothesis, the normalization of the PI3K/AKT/mTOR pathway after CBDV administration is observed at a time point when CBDV is still Figure 7 . Effect of chronic CBDV treatment on (a) AEA, 2-AG, PEA and OEA contents and (b) protein levels of the main endocannabinoid synthetic and degrading enzymes NAPE-PLD, DAGLα, FAAH and MAGL in hemisected brains of Mecp2 WT and KO mice. (c) Representative blot images correspond to the results of one experiment out of four. Data are expressed as mean ± SEM of three to six animals per group and were analyzed by two-way ANOVA followed by Tukey's multiple comparison test. *p<0.05, **p<0.01, ***p<0.001 vs WT-vehicle; °p<0.05, °°p<0.01, °°°p<0.001 vs KO-vehicle. recovering memory deficits but is no longer effective towards motor and neurological signs (i.e. 9 weeks of age).
As reduction of nuclear volumes represents a consistent feature of Mecp2 deficiency at the cellular level (Gadalla et al., 2013; Giacometti et al., 2007) , we assessed whether CBDV treatment could affect this parameter. Analysis of nuclear volumes indicates that CBDV did not rescue nuclear size in the layer V of the mPFC and only a partial effect was observed in the CA1 area of the hippocampus of Mecp2 mutant mice, suggesting CBDV's inability to recover this morphological alteration at least at the end of the treatment schedule.
A previous study found increased levels of GPR55 receptor in RTT mouse hippocampus (Vigli et al., 2018) , hence we have checked in this study for possible changes in other components of the endocannabinoid system. Interestingly, the expression of brain CB1 and CB2 receptors is up-regulated in Mecp2-deficient mice, and chronic CBDV treatment at doses of 2, 20 and 200 mg/kg significantly normalized the levels of both receptors at this advanced stage of the phenotype progression. Given that CBDV binds to CB1 and CB2 receptors with very weak affinity (Amada et al., 2013; Hill et al., 2012a Hill et al., , 2013 Iannotti et al., 2014; Rosenthaler et al., 2014) , we hypothesize that normalization of CB1 receptor expression following CBDV treatment in Mecp2 KO mice might occur indirectly as a consequence of its ability to modulate endocannabinoid signalling, namely by increasing AEA levels and hence down-regulating cannabinoid receptor expression. Indeed, chronic CBDV administration at doses of 2, 20 and 200 mg/kg increased AEA levels and elevated OEA content in Mecp2 mutant mice, effects that are associated with reduced FAAH expression and, only for the highest dose tested (i.e. 200 mg/kg), with enhancement of NAPE-PLD expression. Furthermore, CBDV greatly reduced 2-AG levels both in WT and KO mice. This effect might be exerted at least in part via reduction of DAGLα expression, although the doses that were more efficacious at reducing 2-AG levels were also the ones least efficacious at exerting this effect. It is possible that CBDV reduces 2-AG levels also via its previously reported ability to inhibit DAGLα activity in vitro (Bisogno et al., 2003; De Petrocellis et al., 2011) . Thus, in our experimental conditions CBDV is associated with enhancement of AEA and OEA levels likely through inhibition of FAAH and reduction of 2-AG, possibly in part through inhibition of DAGLα.
Up-regulation of CB1 and CB2 receptors and down-regulation of FAAH levels were also present in naïve 9-week-old Mecp2 KO mice (see Supplementary Figure S5 ), indicating that these changes did not arise from chronic handling procedure (Sciolino et al., 2010) .
It is not possible from our data to draw any conclusion as to whether alterations of the endocannabinoid system in Mecp2 mutant mice sustain the phenotype or represent a compensatory mechanism. Similarly, further studies are needed in order to assess whether CBDV effects on the components of the endocannabinoid (AEA and 2-AG) and endocannabinoid-related (OEA) signalling systems are a mere consequence of or, instead, contribute to its therapeutic effect. The observation that, unlike BDNF and p-rpS6, endocannabinoid receptors and endocannabinoid enzymatic machinery are not altered in the brain of apparently asymptomatic 4-week-old Mecp2 KO mice possibly suggests that the expression of the different components of the endocannabinoid system could be dynamically regulated during phenotype progression in Mecp2 KO mice. However, any conclusion on the role of the endocannabinoid system in this animal model must await the investigation of the effects of drugs specifically targeting the single components of the system both at baseline and following CBDV treatment. Two major limitations should be taken into account when interpreting results from this study. First, Western blot experiments were carried out on hemibrains rather than discrete brain regions, and future studies must test the molecular alterations in different brain structures to determine whether these changes are universal or brain region-specific. Second, all the neurochemical characterizations have been performed at the end of CBDV treatment, when the compound was still effective in recovering cognitive deficits but no longer beneficial towards neurological and motor signs. Thus, it cannot be excluded that different modifications could have been observed as a consequence of CBDV administration if the same analysis had been carried out at earlier time points (i.e. at 7 weeks of age when CBDV showed efficacy also towards neurological and motor signs). Accordingly, when biochemical investigations were performed at an early symptomatic stage of the disease, they failed to reveal any defect in BDNF and IGF1 levels as well as in the phosphorylation level of the rpS6 in the brain of MeCP2-308 mice treated with either vehicle or CBDV (Vigli et al., 2018) . Importantly, our data obtained at this advanced stage of the disease highlight that CBDV treatment can normalize BDNF/IGF1 levels as well as the defective PI3K/ AKT/mTOR pathway in Mecp2 mutant mice, possibly contributing to the restoration of cognitive deficits.
Despite these limitations, this paper demonstrates that chronic CBDV administration exerts an enduring and complete rescue of recognition memory deficits in Mecp2 mutant mice, an effect that is associated with the normalization of BDNF, IGF-1 and rpS6 phosphorylation levels as well as CB1 and CB2 receptor expression. Regarding neurological and motor signs, our data support previous findings indicating that CBDV can ameliorate neurological and motor signs during an early symptomatic phase of the disease (Vigli et al., 2018) but highlight that this effect is only transient and is lost at advanced stages of the phenotype progression.
As a whole, available evidence encourages the investigation of the molecular mechanism(s) by which CBDV can affect behavioural and molecular parameters in this animal model as well as a more specific evaluation of CBDV's efficacy in female models of RTT-like symptoms.
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